Accelrys to Acquire Synomics | GenomeWeb

NEW YORK, June 21 - Accelrys announced it will acquire Synomics in a stock transaction valued at $4 million, the companies announced Thursday.

Accelrys, based in San Diego and Cambridge, UK, and a subsidiary of Pharmacopeia of Princeton, NJ, agreed to acquire all outstanding stock of privately-held Synomics. The companies believe the transaction will be completed within several days. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.